Liverpool-based Applied Nutrition plc, the sports nutrition, health, and wellness brand, has published a strong update on trading for its financial year ended July 31, 2026, and an outlook for the financial year ending July 31, 2027.

“Further to the announcement on 1 June 2026, trading continued to be strong with sustained demand across the Group’s markets and channels,” said Applied Nutrition.

“Excluding any amounts from the acquired trade and assets of Nutrablend in June, the Board now expects FY26 adjusted EBITDA to be ahead of consensus market expectations, increasing by 40% year-on-year to approximately £43.3m (FY25: £30.9m).

“Additionally, revenue is ahead of market expectations having increased 50% year-on-year to £160m (FY25: £107m).

“Net cash (excluding IFRS 16 liabilities) at the close of FY26 was £15.9m, following the acquisition of the trade and assets of Nutrablend, capital expenditure on the production extension and increased working capital to support growth.”

Applied Nutrition went public in a London IPO at £1.40 per share in October, 2024. It’s shares have since soared to around £3.18 to increase its stock market value to almost £800 million.

In its FY27 outlook, the Liverpool firm said: “Building on the strong momentum achieved in FY26, the Group now expects total adjusted EBITDA for FY27 to grow year-on-year to approximately £49m (+13% year-on-year) and revenue to increase to approximately £205m, both ahead of current consensus market expectations.

“While the Board expects continued strong revenue and EBITDA growth across the Group, FY27 EBITDA margin is expected to decrease slightly from FY26 levels.

“This reflects an increased revenue contribution from the US, together with significantly higher whey protein costs and a greater proportion of sales from whey-based products, partly following the very successful relaunch of Critical Whey in FY26.”